20,971 results match your criteria Anticancer research[Journal]


Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer.

Anticancer Res 2019 Feb;39(2):1085-1090

Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago, Japan.

Background/aim: Nutritional status is strongly associated with cancer prognosis. The aim of this study was to identify the most useful combination of nutrition-related serum markers for predicting prognosis of patients with colorectal cancer (CRC).

Patients And Methods: A total of 523 patients who underwent proctocolectomies for CRC at our hospital were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13217DOI Listing
February 2019

Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern.

Anticancer Res 2019 Feb;39(2):1079-1083

Laboratory of Bicohemistry and Genetics, Hospital Clinic, August Pí i Sunyer Biomedical Research Institute - IDIBAPS, Barcelona, Spain

Aim: To confirm that the carbohydrate antigen 19.9 (CA 19.9) protein can be evaluated by determining changes in the β2 zone in protein electrophoresis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13216DOI Listing
February 2019

Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer.

Anticancer Res 2019 Feb;39(2):1073-1078

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.

Background: Body weight, especially lean body mass, significantly decreases after gastrectomy. Postoperative surgical complications are a major risk factor for changes in body weight and body composition after gastrectomy. However, the influence of postoperative surgical complications after gastrectomy on body weight and body composition changes remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13215DOI Listing
February 2019

Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.

Anticancer Res 2019 Feb;39(2):1067-1072

Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Background/aim: In renal cell carcinoma (RCC), sorafenib was the first targeted agent demonstrating a definitive benefit in a large phase III clinical trial. The objective of this study was to assess the clinical outcomes of 42 consecutive RCC patients with metastases solely to the lung who received sorafenib as a second-line systemic agent.

Patients And Methods: Of the 42 patients, 14 (33. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13214DOI Listing
February 2019
1 Read

Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.

Anticancer Res 2019 Feb;39(2):1059-1065

Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.

Background/aim: Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown.

Patients And Methods: Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13213DOI Listing
February 2019
2 Reads

Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy.

Anticancer Res 2019 Feb;39(2):1051-1057

Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Background/aim: New drugs for metastatic colorectal cancer (mCRC) have been recently developed for use in later-line chemotherapy and have contributed to further prolongation of the survival of patients. However, in later-line chemotherapy, treatment failure may lead to discontinuation of chemotherapy and the transition to best supportive care. Therefore, a biomarker able to predict the effects of later-line chemotherapy is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13212DOI Listing
February 2019

Uptake of F-Fluorodeoxyglucose in Major Salivary Gland Cancer Predicts Survival Adjusting for Pathological Stage.

Anticancer Res 2019 Feb;39(2):1043-1049

Department of Head and Neck Surgery, Aichi Cancer Center, Nagoya, Japan.

Aim: To investigate whether F-fluorodeoxyglucose uptake is associated with overall survival in patients with major salivary gland cancer using univariate and multivariate analyses after adjusting for pathological stage (eighth edition of the International Union Against Cancer).

Patients And Methods: A total of 32 patients with major salivary gland cancer treated with curative surgery were enrolled. Parameters for F-fluorodeoxyglucose uptake were assessed by positron-emission tomography combined with computed tomography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13211DOI Listing
February 2019

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Anticancer Res 2019 Feb;39(2):1035-1041

Department of Neuro-Oncology, AP-HM, CHU Timone, Marseille, France.

Background/aim: Secondary leptomeningeal gliomatosis (LG) is a rare and severe progression pattern of glioma. Our objective was to evaluate the characteristics and outcome of patients with LG.

Patients And Methods: We retrospectively reviewed 31 patients diagnosed with secondary LG. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13210DOI Listing
February 2019
3 Reads

Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.

Anticancer Res 2019 Feb;39(2):1029-1034

Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan.

Aim: This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age.

Patients And Methods: Patients were divided into groups under the age of 75 years (n=62), and 75 years and over (n=17). The treatment period with TAS-102 tablet, reasons for discontinuation, adverse events (AEs), and overall survival (OS) were compared between the groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13209DOI Listing
February 2019
5 Reads

Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment.

Anticancer Res 2019 Feb;39(2):1019-1027

Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University "Sapienza", St. Andrea Hospital, Rome, Italy.

Background/aim: Although reckoned necessary for survival benefit, neoadjuvant chemotherapy (NAC) of gastric cancer (GC) patients has so far provided questionable results. Consequently, searching for new and clearer systems of response to NAC, post-NAC re-evaluation and prognostic prediction appears essential. The purpose of this study was to examine endogastric cytopathology and hemoglobin level count as new features, potentially useful for GC patients after NAC. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13208DOI Listing
February 2019
1 Read
1.872 Impact Factor

Use of a Reinforced Triple-row Stapler Following Distal Pancreatectomy Reduces the Incidence of Postoperative Pancreatic Fistula in Patients With a High BMI.

Anticancer Res 2019 Feb;39(2):1013-1018

First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Background/aim: Although perioperative management and operative techniques for pancreatic surgery have improved, postoperative pancreatic fistula (POPF) remains the major cause of morbidity and mortality following distal pancreatectomy (DP). The purpose of this study was to evaluate the superiority of the reinforced stapler compared to the bare triple row stapler.

Patients And Methods: A total of 93 patients who underwent DP at the First Department of Surgery at Yamanashi University were examined. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13207DOI Listing
February 2019
1 Read

Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer.

Anticancer Res 2019 Feb;39(2):1005-1012

Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan college of Medicine and Asan Medical Center, Seoul, Republic of Korea

Background/aim: The aim of this study was to investigate the relationship between age and long-term survival among patients who underwent pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC).

Patients And Methods: A total of 916 patients who underwent PD for curative resection of PDAC were included in this study. Patients were divided into younger (n=726, <70 years) and older (n=190, ≥70 years), and the overall survival (OS) between the two groups was compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13206DOI Listing
February 2019

Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.

Anticancer Res 2019 Feb;39(2):999-1004

Department of Uro-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.

Background: Pazopanib is an effective treatment option for renal cell carcinoma (RCC). However, the therapy is often limited by the appearance of adverse events (AEs), including nausea/vomiting, hepatic impairment, hand-foot syndrome, diarrhea, hypertension and oral mucositis. Early management of AEs is, therefore, extremely important in order to maximize treatment outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13205DOI Listing
February 2019
1 Read

Significance of Lateral Pelvic Lymph Node Size in Predicting Metastasis and Prognosis in Rectal Cancer.

Anticancer Res 2019 Feb;39(2):993-998

Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Aim: To evaluate the clinical significance of lateral pelvic lymph node (LLN) size in predicting pathological metastasis and prognosis in rectal cancer treated with preoperative chemoradiotherapy (CRT) followed by surgery.

Patients And Methods: Fifty-two patients with rectal cancer who underwent curative surgery after preoperative CRT were included. Fifteen patients underwent total mesorectal excision (TME) alone, while 37 patients underwent TME with LLN dissection for clinical LLN metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13204DOI Listing
February 2019
1 Read

Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.

Anticancer Res 2019 Feb;39(2):987-992

Department of Gastroenterological Surgery, Osaka City University, Graduate School of Medicine, Osaka, Japan.

Background: Sarcopenia is known to have an important influence on postoperative complications in several diseases, and on the prognosis of patients with cancer. However, whether sarcopenia is associated with complications and prognosis after gastrectomy in patients with gastric cancer remains controversial. This study evaluated the impact of the preoperative muscle mass on postoperative complications of gastric cancer surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13203DOI Listing
February 2019
1.872 Impact Factor

Postoperative Pneumonia After Esophagectomy and Systemic Inflammatory Response Syndrome.

Anticancer Res 2019 Feb;39(2):979-985

Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

Background/aim: The aim of this study was to determine the association between post-esophagectomy pneumonia and the presence of pathogenic organisms in the sputum or pharynx and postoperative systemic inflammatory response syndrome (SIRS).

Materials And Methods: This retrospective study included 98 patients diagnosed with esophageal cancer who had undergone esophagectomy.

Results: Postoperative pneumonia was observed in 24 patients (24. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13202DOI Listing
February 2019

Impact of Metabolic Parameters of F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma.

Anticancer Res 2019 Feb;39(2):971-977

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan.

Background: The aim of this study was to identify the prognostic impact of metabolic parameters of F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) in patients with intrahepatic cholangiocarcinoma (IHCC) undergoing hepatic resection.

Patients And Methods: Twenty-four patients with IHCC who underwent surgical resection were enrolled and F-FDG PET parameters maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured, as well as overall and recurrence-free survival.

Results: High TLG was significantly associated with large tumor size and high carbohydrate antigen 19-9 level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13201DOI Listing
February 2019
1 Read

Impact of Repeated Hepatectomy on Liver Regeneration in Hepatocellular Carcinoma: A Propensity Score-based Analysis.

Anticancer Res 2019 Feb;39(2):965-970

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Background: Repeated hepatectomy is one of the most curative treatments for recurrent hepatocellular carcinoma (HCC). However, it is not clear whether the remnant liver has the same regenerative ability in repeated hepatectomy. This study assessed the regenerative ability of remnant liver after primary and secondary hepatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13200DOI Listing
February 2019
1 Read

Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.

Anticancer Res 2019 Feb;39(2):957-964

Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Background/aim: For prostate cancer, positive surgical margins are considered an important predictor of biochemical recurrence. However, biochemical recurrence is observed in approximately 20% of cases, even with negative surgical margins, and some cases require salvage therapy. The elevated expression of low-molecular-weight protein tyrosine phosphatase (LMW-PTP, MW 18 kDa) is associated with a poor prognosis of certain cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13199DOI Listing
February 2019

County Median Family Income Is an Independent Prognostic Factor for Stage IV Anaplastic Thyroid Cancer.

Anticancer Res 2019 Feb;39(2):949-956

Division of Endocrinology, Department of Internal Medicine, St Vincent Hospital, Worcester, MA, U.S.A.

Background/aim: Advanced anaplastic thyroid cancer (ATC) is a rare, but highly aggressive malignancy, and its prognostic factors need to be further explored. We examined socioeconomic factors' predictive effect for survival performance in stage IV ATC patients.

Materials And Methods: Using the Surveillance, Epidemiology, and End Results database, we collected 1,048 cases with stage IV anaplastic thyroid cancer (ATC) from 2004 to 2015. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13198DOI Listing
February 2019
2 Reads

Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma.

Anticancer Res 2019 Feb;39(2):941-947

Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.

Background/aim: Intrahepatic cholangiocarcinoma (IHCC) is characterized by poor prognosis, and postoperative recurrence remains a problem. Thus, prognostic markers for IHCC are greatly needed. Recently, inflammatory factors were reported to be related to tumor progression and recurrence in various cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13197DOI Listing
February 2019
1 Read

Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.

Anticancer Res 2019 Feb;39(2):933-939

Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Background/aim: The objective of this study was to determine if sarcopenia was a predictor of poor prognosis in patients with cervical cancer (CC) undergoing concurrent chemoradiation therapy (CCRT) or radiation therapy (RT).

Materials And Methods: A total of 236 patients with CC undergoing CCRT or RT were retrospectively examined. We determined if clinical characteristics and survival were correlated with pretreatment sarcopenia, measured as psoas muscle index (PI) or skeletal muscle index (SMI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13196DOI Listing
February 2019
1 Read

Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.

Anticancer Res 2019 Feb;39(2):923-931

Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan.

Background/aim: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) has not yet been fully determined. The aim of this study was to investigate the optimal management of EGFR-mutant NSCLC patients with BM.

Patients And Methods: A multicenter retrospective study was performed on the clinical outcomes of 81 advanced/recurrent EGFR-mutant NSCLC patients with BM treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) (gefitinib n=52 or erlotinib n=29). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13195DOI Listing
February 2019
1 Read

Diagnostic Utility of Third-Look, Contrast-Enhanced Sonography Followed by Needle Biopsy for MRI, But Not Second-look Ultrasonography-detected Breast Lesions.

Anticancer Res 2019 02;39(2):915-921

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Background/aim: To clarify the diagnostic utility of third-look, contrast-enhanced ultrasonography (CEUS) for MRI-detected breast lesions undetectable by unenhanced, second-look ultrasonography (MRI+/US- lesions).

Patients And Methods: Clinical stage 0-IIA breast cancer patients who underwent CEUS for incidental MRI+/US- lesions (n=27; cohort 1) and patients with breast lesions detected only by MRI, to be examined by CEUS (n=15; cohort 2), were retrospectively analyzed.

Results: Of the 42 MRI+/US- lesions, 23 (55%) were detected by CEUS and then examined by needle biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13194DOI Listing
February 2019
1 Read

Carbon Ion Radiotherapy in the Management of the Tumors of the Peripheral Nervous System.

Anticancer Res 2019 Feb;39(2):909-913

National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.

Background/aim: Malignant peripheral nerve sheaths tumors (MPNST) are rare, highly aggressive and radioresistant tumors of soft tissue. Carbon ion radiotherapy (CIRT) seems to be an attractive treatment option when surgery is not possible or refused by the patient. The aim of this study was to report our preliminary results (outcomes and toxicity) of CIRT in the treatment of MPNSTs. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13193DOI Listing
February 2019
3 Reads

Neuroendocrine Tumor of the Hilar Bile Duct.

Anticancer Res 2019 Feb;39(2):903-907

Department of Gastroenterological Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan

Neuroendocrine tumors usually develop in the gastrointestinal tract, pancreas, and lung. Therefore, a neuroendocrine tumor of the bile duct is quite rare. We present a 59-year-old-male patient whose preoperative diagnosis was hilar cholangiocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13192DOI Listing
February 2019
1 Read

Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review.

Anticancer Res 2019 Feb;39(2):897-902

Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.

Background: Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations.

Case Studies: Here, two patients with unresectable stage III NSCLC carrying mutations in the ALK (case 1) and EGFR (case 2) genes are presented. Treatment of the patient carrying an ALK mutation with an ALK inhibitor and the patient carrying an EGFR mutation with an EGFR inhibitor resulted in dramatic and durable responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13191DOI Listing
February 2019
1 Read

Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer.

Anticancer Res 2019 Feb;39(2):891-895

Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

Background/aim: To investigate outcomes of patients with cervical cancer who received radiation therapy for extrapelvic lymph node recurrence after initial pelvic radiotherapy.

Patients And Methods: The treatment charts of 20 patients were retrospectively reviewed, and factors influencing patient's prognosis were statistically analyzed.

Results: The three-year in-field tumor control rate was 55% and overall survival (OS) at 2, 3, and 5 years was 55%, 45%, and 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13190DOI Listing
February 2019

Clinical Significance of Preoperative Hepatocellular Carcinoma With High Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.

Anticancer Res 2019 Feb;39(2):883-889

Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.

Background: The aim of this study was to verify the significance of high Lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3) in patients with hepatocellular carcinoma (HCC) with low AFP.

Materials And Methods: There were 283 patients with low AFP who underwent initial hepatic resection with or without radiofrequency ablation for HCC. Patients were divided into two groups based on AFP-L3 values: >10%: high AFP-L3 (n=24); and ≤10%: low AFP-L3 (n=259). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13189DOI Listing
February 2019

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study.

Anticancer Res 2019 Feb;39(2):875-882

Roche Pharma AG Germany, Grenzach-Wyhlen, Germany.

Background/aim: The combination of bevacizumab (BEV) plus interferon alpha-2a (IFN) constitutes an option for first-line treatment of metastatic renal cell carcinoma. Real-world data from routine clinical practice are rare and were, therefore, collected during this non-interventional study (NIS).

Patients And Methods: A total of 359 patients received at least one dose of BEV (safety set population; SAF), 354 patients had at least one post-dose effectiveness assessment and formed the full analysis set (FAS) of the final analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13188DOI Listing
February 2019
1 Read

Validation and Verification of Three-dimensional Systems in Laparoscopic Distal Pancreatectomy.

Anticancer Res 2019 Feb;39(2):867-874

Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Aim: The three-dimensional (3D) visualization system has been introduced for the technical improvement of laparoscopic surgery, but clinical evidence for its usefulness is lacking. This study aimed to evaluate the usefulness of a 3D system in laparoscopic surgery.

Patients And Methods: Between 2015 and 2016, a randomized controlled trial was performed on 61 patients who underwent laparoscopic distal pancreatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13187DOI Listing
February 2019

Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide.

Anticancer Res 2019 Feb;39(2):863-866

Department of Medical Oncology, Maxima Medical Center, Veldhoven, The Netherlands.

Background/aim: Enzalutamide is prescribed for advanced prostatic cancer patients, regardless of physical comorbidity. We hypothesized that comorbidity negatively affects survival regardless of age, performance status and prostate-specific antigen (PSA) response.

Patients And Methods: All patients (n=106) treated at the ADRZ Medical Center with enzalutamide in the period 2015-2018 and who had undergone at least one PSA response evaluation were included in a multivariate analysis to test which variables independently affected Time to PSA progression (TPSAP) and/or overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13186DOI Listing
February 2019

The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.

Anticancer Res 2019 Feb;39(2):853-861

Department of Surgery, University Hospitals of Leicester NHS Trust, Leicester, U.K.

Background/aim: Previous studies have shown anti-proliferative and anti-apoptotic effects of omega-3 fatty acids (Omegaven®) in vitro and in vivo. Whether this effect can be exploited in patients with advanced esophago-gastric adenocarcinoma is unknown. The present study intended to determine the tumour radiological response and toxicity profile of intravenous omega-3 fish oil infusion when combined with standard palliative chemotherapy, and present the effects of this treatment on plasma cytokine biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13185DOI Listing
February 2019

Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature.

Anticancer Res 2019 Feb;39(2):847-852

Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria.

Background/aim: Colorectal cancer (CRC) is the third most common cancer worldwide. The prognosis between left- and right-sided CRC differs, partly due to baseline differences as vascular supply. The purpose of the present study was to investigate whether there are genetic differences between left- and right-sided CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13184DOI Listing
February 2019

Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Anticancer Res 2019 Feb;39(2):839-845

Department of Surgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

Background: Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have not been previously studied in Finland. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13183DOI Listing
February 2019
10 Reads

Crypts With Corrupted Shapes in Non-polypoid Adenomas.

Anticancer Res 2019 Feb;39(2):833-838

Department of Medicine Solna, Center for Digestive Diseases, Karolinska Institute and University Hospital, Stockholm, Sweden.

Background: Colonic crypts with normal epithelial lining exhibiting corrupted shapes (NECS) have been previously found beneath the adenomatous tissue of polypoid conventional adenomas, in both rats and humans.

Aim: To assess the frequency of NECS in non-polypoid colonic flat adenomas (FAs) and lateral-spreading adenomas (LSAs).

Materials And Methods: Histological hematoxylin and eosin-stained sections from 51 non-polypoid colonic adenomas were scrutinized over a 10-mm field of vision (FOV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13182DOI Listing
February 2019

Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1.

Anticancer Res 2019 Feb;39(2):827-831

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

This report describes the diagnosis and treatment of a 27-year-old patient with neurofibromatosis 1 (NF1) and late progression of a pre-existing optic pathway glioma (OPG) that caused significant reduction in vision. OPG is one of the diagnostic criteria for establishing the diagnosis of NF1. Most common findings of NF1 are café-au-lait spots, axillary and inguinal freckling of the skin, iris hamartoma (Lisch nodules), and tumors of the central nervous system and peripheral nerves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13181DOI Listing
February 2019
1 Read

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.

Anticancer Res 2019 Feb;39(2):815-825

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Background/aim: Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13180DOI Listing
February 2019

Nitrotyrosine (NT), a Nitrosative Stress Biomarker, Plasma Concentrations in Gallstone Disease and Cancer Patients.

Anticancer Res 2019 Feb;39(2):809-814

Department of Surgery, Kuopio University Hospital and School of Medicine, University of Eastern Finland, Kuopio, Finland

Background/aim: The aim of this study was to assess the plasma concentration of the nitrosative stress biomarker nitrotyrosine (NT) in gallstone disease and cancer patients.

Materials And Methods: Initially, 114 patients with symptomatic gallstone disease were randomized into the laparoscopic cholecystectomy (LC) (n=54) and the minicholecystectomy (MC) (n=60) groups. The plasma concentrations of NT were measured just before, immediately after (POP1) and 6 h after operation (POP2). Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13179DOI Listing
February 2019
10 Reads

Patterns of Care in Pediatric Craniopharyngioma: Outcomes Following Definitive Radiotherapy.

Anticancer Res 2019 Feb;39(2):803-807

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, U.S.A.

Background/aim: Few data are available on the utility of definitive radiation therapy (RT) for pediatric craniopharyngioma. This study sought to evaluate practice patterns and patient outcomes using the Surveillance Epidemiology and End Results database from 2004-2014.

Materials And Methods: Overall survival (OS) was compared between five treatment groups, definitive radiation therapy (RT), gross total resection (GTR), subtotal resection (STR), STR+RT, and observation/biopsy only, using Kaplan-Meier analysis and log-rank tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13178DOI Listing
February 2019
1 Read

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Anticancer Res 2019 Feb;39(2):797-802

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Background/aim: This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based therapy.

Patients And Methods: HERA is an international randomized trial of 5,102 women with HER2-positive EBC, who were enrolled to either receive adjuvant trastuzumab or not. In this exploratory analysis, the interaction between autoimmune history and the magnitude of trastuzumab benefit was evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13177DOI Listing
February 2019
1 Read

No Evidence for Increased Brain Tumour Incidence in the Swedish National Cancer Register Between Years 1980-2012.

Anticancer Res 2019 Feb;39(2):791-796

Center for Research and Development, Uppsala University/County Council of Gävleborg, Gävle Hospital, Gävle, Sweden

Background/aim: The main objective of this study was to evaluate if there was an increased incidence of brain tumours between years 1980-2012, a time period when mobile phone usage has increased substantially.

Materials And Methods: From the Swedish Cancer Registry, cases of meningiomas, low-grade gliomas (LGG) and high-grade gliomas (HGG) were identified in patients between 1980-2012. Direct age-standardised incidence rates were used to calculate incidence trends over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13176DOI Listing
February 2019

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.

Anticancer Res 2019 Feb;39(2):781-790

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, U.S.A.

Background: Data on the characteristics of patients who are likely to experience adverse events, both immune-related and non-immune-related, from programmed cell death-1 (PD1) inhibitors are limited.

Patients And Methods: Data from patients who received ≥1 dose of single-agent PD1 inhibitor between August 3, 2011 and August 31, 2016 were obtained from our Institution's pharmacy database. AEs were graded using Common Terminology Criteria for Adverse Events version 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13175DOI Listing
February 2019
2 Reads

Effect of Radiation on the Expression of CVD-related miRNAs, Inflammation and Endothelial Dysfunction of HUVECs.

Anticancer Res 2019 Feb;39(2):771-780

Physiology Unit, School of Medicine, IISPV, Rovira i Virgili University, Reus, Spain.

Background/aim: Radiotherapy (RT) can lead to cardiovascular disease (CVD). Evidence suggests that radiation modulates miRNA levels. Our purpose was to assess the acute response to radiation-induced modulation of the expression of miRNA-146a, miRNA-155, miRNA-221, and miRNA-222, inflammatory response and endothelial dysfunction on endothelial cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13174DOI Listing
February 2019

Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative.

Anticancer Res 2019 Feb;39(2):759-769

Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea

Background/aim: Strategies to enhance the therapeutic ratio of radiotherapy in glioblastoma are warranted. Our aim was to report a novel DNA methyltransferase inhibitor as a potential radiosensitizing agent in glioblastoma.

Materials And Methods: Four glioblastoma cell lines and one normal astrocyte cell line were incubated with a newly-synthetized phthalimido-alkanamide derivative, MA17, and its radiosensitizing effects were assessed. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13173DOI Listing
February 2019
3 Reads
1.872 Impact Factor

Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.

Anticancer Res 2019 Feb;39(2):751-758

School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Background/aim: The anti-cancer effect of high doses of intravenous vitamin C (high-dose vitamin C) remains controversial despite growing evidence that high-dose vitamin C exerts anti-tumorigenic activity by increasing the amount of reactive oxygen species in cancer cells without meaningful toxicities. Therefore, this study attempted to demonstrate the in vitro anti-cancer activity of high-dose vitamin C in combination with conventional treatment in breast cancer.

Materials And Methods: The pro-apoptotic effects of high-dose vitamin C (1. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13172DOI Listing
February 2019
10 Reads

Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.

Anticancer Res 2019 Feb;39(2):745-749

Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland

Background/aim: Protein tyrosine phosphatase (PTP1B) is a potential target for the treatment of type 2 diabetes and cancer. Curcumin and cinnamaldehyde have been previously reported to have antidiabetic and anticancer potentials. The aim of this study was to investigate the effect of curcumin in comparison to cinnamaldehyde on the enzymatic activity of PTP1B and the viability of MCF-7 cancer cells. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13171DOI Listing
February 2019
3 Reads

Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: Evaluation on VEGFR2-positive Cell Lines.

Anticancer Res 2019 Feb;39(2):735-744

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.

Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13170DOI Listing
February 2019
1 Read

Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells.

Anticancer Res 2019 Feb;39(2):727-734

Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland.

Background: Incidence of cancer is still increasing. Chemotherapy is often unsuccessful; moreover, anticancer drugs cause serious side-effects. It is necessary to develop effective agents for combination therapies that would increase antitumor effects of treatment and reduce its side-effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13169DOI Listing
February 2019

The -Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells.

Anticancer Res 2019 Feb;39(2):721-726

School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan, R.O.C.

Background/aim: Hepatitis B virus-encoded X protein (HBx) plays a pivotal role in hepatocellular carcinoma (HCC) progression and treatment resistance. Interestingly, our previous study unexpectedly showed that full-length HBx sensitized HCC cells to lapatinib by up-regulating erb-b2 receptor tyrosine kinase 3 (ERBB3). We further aimed to map the exact motif within the HBx sequence responsible for lapatinib sensitization. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13168DOI Listing
February 2019
2 Reads